LP-SBA-15/Ketorolac Nanocomposite: Development, Characterization, and Mathematical Modeling of Controlled Keto Release
Drug-controlled release systems can keep the level of drugs in precise doses in the body above the optimal level and with low toxicity. We propose the nanomaterial LP-SBA-15 as an attractive new host for drug delivery systems due to its high biocompatibility, in vivo biodegradability, and low toxici...
| Authors: | , , , |
|---|---|
| Format: | article |
| Status: | Published version |
| Publication Date: | 2022 |
| Country: | Argentina |
| Institution: | Consejo Nacional de Investigaciones Científicas y Técnicas |
| Repository: | CONICET Digital (CONICET) |
| Language: | English |
| OAI Identifier: | oai:ri.conicet.gov.ar:11336/188234 |
| Online Access: | http://hdl.handle.net/11336/188234 |
| Access Level: | Open access |
| Keyword: | DRUG-DELIVERING DEVICE KETOROLAC TROMETHAMINE LP-SBA-15 NANOSCALE MEDICINE NANOSTRUCTURED HOST https://purl.org/becyt/ford/2.10 https://purl.org/becyt/ford/2 |
| Summary: | Drug-controlled release systems can keep the level of drugs in precise doses in the body above the optimal level and with low toxicity. We propose the nanomaterial LP-SBA-15 as an attractive new host for drug delivery systems due to its high biocompatibility, in vivo biodegradability, and low toxicity. LP-SBA-15/Ketorolac was prepared and characterized by XRD, FTIR, UV-Vis DRS, TEM, and texture analysis, determining the adsorption capacity and its release and achieving the required therapeutic efficacy. The host shows the ordered mesoporous nanochannels with a diameter of 11-12 nm, maintaining the structure with the incorporation of Keto. The mechanism of drug release from the LP-SBA-15 host was evaluated. Different mathematical models were used to adjust the experimental data, the Ritger-Peppas model followed by the Weibull model the best ones. The promising results we obtained for the release of the drug thoroughly using the new material, reaching a rapid initial release rate, and maintaining a constant rate afterward, allow us to maintain the concentration of the drug in the therapeutic efficacy range, applying it largely to the treatment of diseases that require a rapid response. |
|---|